New Two-Drug attack on Tough-to-Treat lung cancer
NCT ID NCT07264816
Summary
This study is testing whether a new drug called BL-M07D1 works better when combined with an existing immunotherapy (pembrolizumab) for people with a specific type of advanced lung cancer that has too much HER2 protein. It will involve about 80 adults whose cancer has spread and cannot be removed by surgery. The main goal is to see if this combination can shrink tumors and control the cancer for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact
Conditions
Explore the condition pages connected to this study.